Menu
HBI Biotech Sciences (former Envigo) is the leading & largest provider of preclinical research services in Israel. With a dedicated team of experts and a commitment to excellence, we strive to advance scientific discoveries and support our clients in every step of the way.
A leading one-source preclinical Contract Research Organization (CRO) offering tailor-made solutions and guideline-based solutions. The first established and GLP-accredited CRO in the county. With over 30 years of experience, we specialize in supporting clients through every stage of discovery, research and development of pharmaceuticals, Medical Device, diagnostic tools and materials.
Our commitment is to provide the best client’s experience: responsive, professional, objective, transparent and providing top quality service, work and writing, which meets international standards. We are also committed to support our clients after submission, when the need arise to provide data and answers to regulatory authorities, all the way until approval.
Explore our website to discover more about our in vivo and in vitro services, and feel free to reach out for personalized assistance or to discuss potential collaborations. Thank you for considering HBI Biotech Sciences as your trusted partner in preclinical research.
Our vision is to be the leading full-service CRO providing the highest quality preclinical research to support our clients in bringing novel therapies from discovery through early clinical development.
We aim to achieve this by continually investing in state-of-the-art facilities and equipment, recruiting and retaining top scientific talent, implementing rigorous quality control procedures, and nurturing a collaborative culture focused on scientific excellence and customer service.
Our preclinical services, ranging from pharmacology and toxicology to bioanalysis and drug metabolism, will enable clients to make data-driven decisions about their compounds and advance only the most promising candidates into clinical trials.
Our vision is to sustain best quality the standards in preclinical research, offering unmatched expertise, top quality, tailored and standard support. As Israel’s leading preclinical CRO we aim to be your go-to collaborator, transforming challenges into achievements considering our professional insights and extensive experience.
Our vision is to be the leading full-service CRO providing the highest quality preclinical research to support our clients in bringing novel therapies from discovery through early clinical development.
We aim to achieve this by continually investing in state-of-the-art facilities and equipment, recruiting and retaining top scientific talent, implementing rigorous quality control procedures, and nurturing a collaborative culture focused on scientific excellence and customer service.
Our preclinical services, ranging from pharmacology and toxicology to bioanalysis and drug metabolism, will enable clients to make data-driven decisions about their compounds and advance only the most promising candidates into clinical trials.
Our vision is to sustain best quality the standards in preclinical research, offering unmatched expertise, top quality, tailored and standard support. As Israel’s leading preclinical CRO we aim to be your go-to collaborator, transforming challenges into achievements considering our professional insights and extensive experience.
At HBI Biotech Sciences, our mission is to deliver high-quality preclinical services that empower researchers and contribute to breakthroughs in science. We combine expertise, innovation, and a client-focused approach to provide tailored solutions for your unique research needs.
Over the years, HBI Biotech Sciences has proudly achieved multiple prestigious accreditations, including GLP (Good Laboratory Practice) and GMP (Good Manufacturing Practice) for batch release testing, among others.
We are honored to be the first CRO in our field to attain GLP certification for rodents, large animals and histopathology, underscoring our commitment to excellence and adherence to the highest industry standards.
These accreditations reflect our dedication to quality, safety, and reliability in all aspects of our preclinical research and development services.
For work with large & small animals
In Vivo & In Vitro
Extended certificate for histopathology Test site & large animals Test site
For health monitoring of
laboratory animals
Permit for work with cannabis
Our team consists of experienced professionals dedicated to ensuring the success of your research projects.
From in vivo studies to in vitro experiments, we offer a wide range of services to address diverse research requirements.
We stay at the forefront of scientific advancements, incorporating the latest technologies and methodologies into our services.
Your success is our priority. We work closely with you, fostering collaboration and communication throughout the research process.
We specialize in a comprehensive range of non-clinical safety and efficacy testing, ensuring top-notch quality in every project.
Our integrated programs and services are designed to support all phases of drug and medical device development, tailored specifically to meet your unique needs.
We excel in leveraging HBI's full spectrum of services and world-class expertise. We are committed to designing and implementing research programs that not only meet but exceed your expectations.
Our approach is to provide solutions that are custom-fitted to your project's requirements, ensuring a seamless and successful development process.
OECD GLP compliant studies suitable for submission to Regulatory Authorities
Guidelines / Standards followed:
Chemicals
Agrochemicals
Pharmaceuticals
Medical Devices (MD)
GMP compliant Assays for Batch Release
Explore our website to discover more about our in vivo and in vitro services, and feel free to reach out for personalized assistance or to discuss potential collaborations. Thank you for considering HBI Biotech Sciences as your trusted partner in preclinical research.
Dr. Nati Ezov has co-founded Harlan Biotech Israel (known today as HBI Biotech Sciences and Harlan Laboratories) in 1995 and since 1996 he serves as the CEO of both companies.
As an entrepreneur in the fields of biopharmaceutical research and development, Nati led HBI Biotech Sciences (HBI) from a small CRO (under global ownership) providing specific preclinical research models and services, to be the largest private Israeli CRO company that provides full designated service to meet the requirements of our clients, local and abroad. Taking advantage of the knowledge and experience gained under the different global ownerships, he pioneered with implementation of international quality standards for preclinical trials in Israel, fostering and cultivating global collaborations and partnerships to become a prominent figure in the local preclinical research arena.
Prior to the founding of HBI, Nati was Chief Animal Technician and the Chief Veterinary Officer at Bio-Technology General Ltd. (BTG), where he gained knowledge and experience in maintenance of animals’ facilities and treatment, health care and use of laboratory animals. As a worldwide expert in the field, he provided consultation to many biotechnology companies through their different preclinical and clinical R&D stages.
Dr. Ezov was among the four veterinarians to establish the Israeli Laboratory Animal Forum (ILAF) in 1998, aimed to serve as the primary professional body in Israel, advancing the fields of laboratory animals medicine and research and the Israeli representative in the European societies.
Throughout the years, Nati has attended workshops and completed professional courses worldwide such as microsurgical procedures workshop (England), pharmacokinetics and bioavailability of drugs (Israel) and laboratory animal sciences course (the Netherland). He has collaborated with many researchers from international institutions and appears in tens of peer-reviewed scientific articles.
Dr. Ezov holds a degree of Doctor of Veterinary Medicine (DVM) from the Hebrew University of Jerusalem (HUJI), and a M.Sc and B.Sc from the Faculty of Agriculture, HUJI. Additionally, Nati was certified as a diplomate of expertise in laboratory animal medicine from the European College of Laboratory Animal Medicine (ECLAM) and as a Veterinary Specialist in Laboratory Animal in the veterinary services by the Ministry of Agriculture in Israel.
Dr. Efrat Sharvit joined HBI Biotech Sciences on January 2013 and serves as head of the in vitro department since June 2014.
As such, Efrat provides our clients with a standard and bespoke comprehensive in vitro research services, biological assays and non-cell-based lab testing methods for safety or efficacy testing for drug/product candidates.
Efrat ensures that our work and studies meet the highest standards of quality and efficacy.
As the primary point of contact for in vitro studies, Efrat plays a crucial role in understanding the client’s unique research needs in the in-vitro field. With a focus on high standards and quality experiences, Efrat will work with you closely to achieve the best results and to ensure product alignment with both regulatory requirements and the specific objectives of your pre-clinical project.
Prior to her joining HBI, Efrat served as a Researcher at the Gastroenterology lab in Ichilov Hospital.
Efrat holds a PhD in Medical Sciences (research areas: Molecular Biology and liver fibrosis both in vitro and in vivo), a Master’s in nanotechnology in plants from the Department of Life Science, Ben-Gurion University, and a bachelor’s degree from Ben-Gurion University.
With over 20 years of scientific experience in the fields of Biology and medicine, Efrat together with her team of experts, will assist you to design and execute successful pre-clinical studies.
Dr. Shlomit Dachir-Kanot joined HBI Biotech Sciences as Chief Scientific Officer in January 2025. With over 35 years of research and leadership experience, Shlomit brings a combination of scientific expertise and management skills to the team. Her work is focused on advancing HBI’s pharmacology and preclinical research, particularly in the areas of toxicology, pharmacology, and injury models.
As the primary point of contact for our clients, Shlomit plays a crucial role in shaping the strategic direction of HBI’s research efforts. She ensures that all studies and projects adhere to the highest scientific and regulatory standards and collaborates closely with clients to design study protocols that meet both regulatory requirements and the specific objectives of their pre-clinical projects.
Before joining HBI, Shlomit served as Head of the Pharmacology Department at the Israel Institute for Biological Research, where she led numerous studies in pharmacology, toxicology, and neuroscience. She also managed large-scale research projects and multidisciplinary teams, focusing on the development of treatments for chemical warfare agents and toxic industrial chemicals.
Shlomit holds a Ph.D. in Animal Science from the Hebrew University of Jerusalem, an MSc. in Animal Science from Texas A&M University, and a BSc. in Agricultural Science from the Hebrew University. Throughout her career, she has been committed to research excellence and is passionate about advancing science to improve public health and safety.
Dr. Tal Levin-Harrus has joined HBI Biotech Sciences on December 1996 and serves as the company’s Facility Manager and the Institutional Veterinarian since January 2000.
As part of her role, Tal is leading HBI mentoring and training programs of Study Directors (SD’s) and Head of Departments (HOD’s) and supervises all veterinary aspects. Tal liaise with the internal staff as well as with external clients in various stages of studies’ execution, from initial steps of quoting and planning the study design and up to reporting and archiving.
As an expert in Laboratory Animals Medicine and the Institutional Veterinarian Tal is leading the establishment of complicated surgical procedures and convey them to the technical staff.
Prior to her joining HBI, Tal served as a Veterinarian in the Hebrew University Veterinary Hospital as part of an Internship Program.
Tal holds a DVM degree from the Koret School of Veterinary Medicine (the Hebrew University of Jerusalem) and an expert certificate in the field of Laboratory Animals Medicine.
With over 25 years of experience working in a GLP-compliant environment, communicating with internal teams and external clients as well as with regulatory authorities and veterinarian practicing in Laboratory Animals, Tal manages HBI team and operations to ensure that our services and work meet the highest standards of quality, efficacy and GxP.
As the Facility Manager at HBI, Tal plays a crucial role in training, mentoring, guiding and supervising the work of SD’s and HOD’s. Under Tal’s leadership, our clients can be assured that all studies meet both regulatory requirements and the specific objectives of their pre-clinical projects.
Dr. Julia Vilensky joined HBI Biotech Sciences on May 2006 and serves as head of QA since July 2020.
As such, Julia assures all studies are in compliance with GLP and GMP national and international regulations. In charge of QA activities, Julia ensures that our work and documentation meet the highest standards of quality and efficacy.
As the primary point of Quality Assurance program, Julia plays a crucial role in planning and conducting audits (Facility based, Study based and Procedure based), document review (including Study Plans, Study Reports, SOP etc) and providing support and quality advice both to our team and to our clients. With a focus on data quality and integrity, Julia will work with you closely to assure that Study/Test results and documentation meet both regulatory requirements and the specific objectives of your pre-clinical project.
Prior to her assignment as QA manager, Julia served as a QA auditor at HBI Biotech sciences for 14 years. Julia has extensive experience in the quality field where she leads regulatory inspections (ISRAC, MOH, FDA), provides quality training to HBI staff, takes part in internal investigations, and manages CAPA and OOS.
Julia holds a DVM degree from the Hebrew University of Jerusalem and a bachelor’s degree in biology from Tel Aviv University.
With over 18 years of experience in the fields of Quality Assurance in the field of pre-clinical studies, your study will be best monitored for the perfect outcome.
At HBI, we offer expert consulting services to optimize animal facility maintenance and breeding programs.
Our CEO Dr. Nati Ezov can help you with tailored solutions to enhance the efficiency, health, and welfare of laboratory animals.
We offer comprehensive assessments of facility infrastructure, including HVAC systems, biosecurity protocols, and environmental enrichment strategies, to ensure optimal conditions for animal welfare and research integrity. Additionally, we provide strategic guidance on breeding program management, genetic diversity enhancement, and reproductive health monitoring to support sustainable and successful animal colony management.
Whether you’re establishing a new facility or seeking to improve existing operations, HBI is dedicated to fostering excellence in animal care and research outcomes.
HBI comprehensive Good Laboratory Practice (GLP) Archive Service, is designed to ensure the secure and organized storage of your invaluable scientific data and documentation. It is maintained to meet the stringent standards of GLP, providing a secure and controlled environment for the retention of critical records from your preclinical research studies.
With a commitment to data integrity and compliance, our GLP Archive Service offers a systematic and traceable approach to document storage, retrieval, and maintenance.
Whether you require the archiving of raw data, study protocols, pathology slides & blocks, fixed wet tissues, electronic data or quality control records, our service aims to safeguard your research legacy, facilitating regulatory compliance and future scientific inquiries.
Our archiving services can be provided as part of a study or as a stand-alone service.
Partner with us for a reliable and tailored GLP archive solution that ensures the longevity and accessibility of your vital scientific records.
Toxicological pathology is crucial in the evaluation of potential toxic effects of substances on biological tissues and organs.
This field combines pathology and toxicology to assess adverse effects, identify target organs, and elucidate mechanisms of toxicity.
At HBI Biotech Sciences, we provide comprehensive histopathological evaluation services, offering detailed analysis to support risk assessment, regulatory approval, and the safe development of medical devices, pharmaceuticals, chemicals, and other products. Our expertise in toxicological pathology ensures thorough assessment and helps ensure human and environmental safety by identifying potential hazards before they reach the market.
Histopathology evaluation and reporting can be provided as an integral part of the study execution and report or as a stand-alone service. This service may be GLP-compliant or non-GLP as required and may include incorporation of microphotographs in accordance with FDA requirements (e.g., FDA Guidance for Industry issued on March 28, 2023 – General Considerations for Animal Studies Intended to Evaluate Medical Devices) and may include, upon request, the issue of a Histopathology Phase Report.
At HBI, we offer a comprehensive range of bioproducts sourced from both laboratory and farm animals (to some extent), tailored to meet the diverse needs of our clients.
Our offerings include blood products, organs, and tissues, each meticulously collected and processed according to your specific requirements.
Whether you need whole blood, plasma, serum, or other derivatives, our expert team ensures that all blood products are handled with the highest standards of care and precision. Additionally, we provide a variety of organs and tissues, harvested and preserved to maintain their integrity and viability for your research applications. Understanding the critical importance of proper storage, we offer flexible solutions, delivering your bioproducts under various conditions—frozen, refrigerated, or ambient—based on the nature of the materials and your project needs.
Our commitment to quality and customization ensures that you receive reliable, high-quality bioproducts that support your research and development goals.
At HBI, we specialize in performing a variety of in vivo stand-alone special procedures essential for preclinical research. Our expert team is skilled in techniques such as cannulation, splenectomy, castration, and ovariohysterectomy, among others. These procedures are critical for studying disease mechanisms, evaluating therapeutic interventions, and assessing physiological responses in animal models.
We adhere to stringent protocols and ethical standards to ensure the safety, well-being, and humane treatment of all animals involved. Whether you require a single procedure or a combination of techniques, we provide precise and reliable services tailored to meet your specific research objectives. Trust HBI to deliver exceptional results with a focus on scientific rigor and ethical animal care practices.
Ex vivo studies play a pivotal role in our research methodology, allowing us to explore the intricate details of biological processes outside the living organism. In these studies, we carefully extract tissues, cells, or organs from the organism of interest and conduct meticulous analyses in controlled laboratory settings.
Our ex vivo studies serve as a powerful tool for understanding cellular mechanisms, assessing the effects of interventions, and gaining insights that contribute to the advancement of scientific knowledge. By leveraging ex vivo methodologies, we aim to uncover valuable information that can inform and enhance our understanding of various physiological and pathological processes, ultimately contributing to the development of innovative and targeted solutions.
Ex vivo services/studies – abundant possibilities suited for customer’s needs, including establishment on site and using various species as origin. Examples:
Various services for live animals delivered or for samples delivered, such as:
